- Cardinal Health price target raised to $185 from $170 at UBS
Jun 16, 2025
UBS reiterated a Buy rating on Cardinal Health (NYSE:CAH) while raising its price target to $185 from $170 on Monday. The healthcare giant, currently trading near its 52-week high of $162.94, has delivered an impressive 64% return over the past year. According to InvestingPro data, multiple analysts have recently revised their earnings estimates upward for the upcoming period.
The price target increase reflects UBS’s higher estimates for the healthcare services company, with the new target based on a 17x next-twelve-months plus 12-month estimate multiple, up from the previous 16x multiple.
UBS believes Cardinal Health shares should trade closer to peers, noting that CAH shares currently trade at 17x consensus next-twelve-months earnings per share.
This valuation is in-line with competitor Cerner (NASDAQ:CERN) (COR) and below McKesson (NYSE:MCK), which trades at 19x earnings, according to the research firm’s analysis.
The firm maintained its positive outlook on Cardinal Health with the Buy rating unchanged, focusing only on the price target adjustment in Monday’s research note.
In other recent news, Cardinal Health has raised its full-year adjusted earnings per share (EPS) forecast to a range of $8.15 to $8.20, surpassing analyst expectations. The company also provided preliminary guidance for fiscal year 2026, projecting adjusted EPS between $9.10 and $9.30, indicating a 13% growth at the midpoint compared to the current year’s outlook. During its Investor Day, Cardinal Health outlined a long-term target of a 12% to 14% compound annual growth rate for adjusted EPS from fiscal years 2026 through 2028. The company announced strategic initiatives, including investments in Biopharma Solutions and plans to build a new forward distribution center. Cardinal Health also entered a distribution services agreement with Citius Oncology to facilitate the U.S. launch of LYMPHIR™, an FDA-approved immunotherapy. Analysts from TD Cowen and BofA Securities have maintained their Buy ratings on Cardinal Health, with BofA raising the stock price target to $170. The company expects to generate at least $10 billion in total adjusted free cash flow over the next three years and increased its baseline share repurchase plans to at least $750 million per year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
- VSee Health Announces Contract with Top Kidney Care Provider to Add VSee Workflow to Oracle Cerner EHR
Feb 12, 2025 · businesswire.com
SAN JOSE, Calif.--(BUSINESS WIRE)--VSee Health announces a contract with a top five US kidney dialysis service for EHR integration.
- VSEE HEALTH ANNOUNCES CONTRACT WITH TOP KIDNEY CARE PROVIDER TO ADD VSEE WORKFLOW TO ORACLE CERNER EHR
Feb 12, 2025
SAN JOSE, CALIF.--(BUSINESS WIRE)--VSEE HEALTH ANNOUNCES A CONTRACT WITH A TOP FIVE US KIDNEY DIALYSIS SERVICE FOR EHR INTEGRATION.
- Is Oracle (ORCL) the Best Stock Pick You Need to Know in Jim Cramer’s Latest Watchlist?
Sep 14, 2024
We recently compiled a list titled Jim Cramer’s Latest Watchlist: 10 Stock Picks You Need to Know. In this article, we will look at where Apple Inc. (NASDAQ:AAPL) stands among other stock picks in Jim Cramer's latest watchlist.
In a recent episode of Mad Money, Jim Cramer advised investors to hold onto their stocks, anticipating a rebound after the market’s downturn. This advice proved useful as the Dow rose by 484 points or 1.16% and the NASDAQ also climbed by 1.16%, indicating that selling during the market decline was not the best choice.
“Last week, I advised you to hold off on selling everything and just wait, as I believed that once the pain ended, we would see a rebound. The average investor saw gains, with the Dow up 484 points, or 1.16%, and the NASDAQ also climbing 1.16%. While it might not be a full recovery, it shows that selling into Friday’s downturn wasn’t the best strategy.”
Jim Cramer noted that the previous week was tough for economically sensitive and tech stocks, despite a mixed August employment report. This report suggested a balanced economic outlook, not too strong or weak, which initially seemed favorable for those hoping for Federal Reserve rate cuts. Despite this, Wall Street reacted negatively, shifting away from cyclical stocks to more recession-proof sectors like consumer goods and pharmaceuticals, with industries such as industrials and semiconductors being particularly affected.
Cramer observed that recession-proof stocks, such as pharmaceuticals and medical devices, have performed well recently but have seen significant gains, raising concerns about a potential correction.
“Today, recession-proof stocks like pharmaceuticals, drug wholesalers, and medical devices continued to perform well, which is dangerous as these stocks have seen parabolic gains and could be due for a correction.”
He highlighted that historically, when the Federal Reserve is about to cut rates, it signals a shift in investment strategy. With the Fed expected to ease rates soon, Cramer suggests investors consider moving away from recession-proof stocks and look into more cyclical companies that could benefit from economic stimulus. While investing in cyclical stocks during a downturn is challenging, the anticipated rate cuts could make these stocks more attractive. Cramer advises maintaining diversification but being ready to adjust investment strategies based on the economic outlook.
“Historically, when the Fed is about to start cutting rates, we know that it’s time to shift focus. With the Fed leaning towards easing and an expected rate cut next week, it’s time to consider moving away from recession-proof stocks and investing in more cyclical companies. While it’s challenging to buy cyclical stocks during a slowdown, anticipating that the Fed will boost the economy can make them strong investment opportunities. It’s important to maintain diversification but be ready to adjust as needed.”
Story continues
Our Methodology
This article reviews a recent episode of Jim Cramer’s Mad Money, where he talked about several stocks. From there, we picked ten companies and discussed how hedge funds are investing in them. Finally, we rank these companies from those least owned to those most owned by hedge funds.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Oracle Corporation (NASDAQ:ORCL)
Number of Hedge Fund Investors: 93 Jim Cramer highlighted a recent positive report from Oracle Corporation (NASDAQ:ORCL), noting that much of the good news is tied to the expansion of AI data centers. Cramer believes that the sell-off in chip stocks has been overdone, as the reasons for favoring this sector earlier in the year still hold true. He emphasized that the surge in AI spending is genuine, with significant investments in building the necessary infrastructure, as demonstrated by Oracle Corporation (NASDAQ:ORCL)’s latest results.
“This very evening, we got a startlingly good report from Oracle. A lot of the good news came in concert with data centers for AI. Hey, not bad! In the end, I think the chip stocks have sold off way too hard. Every reason we had to like this group earlier this year remains intact. The AI spending boom is very real, and there’s a ton of money being spent to build out the infrastructure, as we heard from Oracle this evening.
More importantly, there’s more to chips than AI. For the past couple of quarters, we’ve been exiting a period of oversupply in the semiconductor market, and we’re now finally seeing some excellent sales growth. Yes, we’re past the point of equilibrium—we’re going up!”
In Q1 2024, Oracle Corporation (NASDAQ:ORCL)’s earnings rose to $2.93 billion, or $1.03 per share, surpassing expectations. Its adjusted earnings of $1.39 per share also beat forecasts of $1.32. Revenue grew by 6.9% to $13.31 billion, driven mainly by its cloud services. The cloud segment, boosted by the acquisition of Cerner Corporation (NASDAQ:CERN), saw a 20% increase year-over-year, reaching $5.3 billion. Oracle Corporation (NASDAQ:ORCL)’s Infrastructure as a Service (IaaS) experienced a remarkable 42% growth, highlighting its successful focus on high-demand cloud and AI services. Additionally, Oracle Corporation (NASDAQ:ORCL) has secured over $12 billion in AI contracts, positioning itself strongly in the AI field. Oracle Corporation (NASDAQ:ORCL)’s future revenue prospects are supported by a substantial $98 billion in remaining performance obligations. With its leadership in cloud technology and expanding AI contracts, Oracle Corporation (NASDAQ:ORCL) is set for continued growth, making it an attractive investment. Carillon Eagle Growth & Income Fund stated the following regarding Oracle Corporation (NYSE:ORCL) in its Q2 2024 investor letter:
“Oracle Corporation (NYSE:ORCL) stock rose to all-time highs after the company announced better than expected cloud infrastructure revenue. Oracle signed dozens of new customers, including two leaders in generative artificial intelligence. The backlog remains, and strong growth appears poised to accelerate.”
Overall ORCL ranks 2nd on our list. While we acknowledge the potential of AAPL, our conviction lies in the belief that under the radar AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than the ones on our list but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article was originally published on Insider Monkey.
View comments
- Jim Cramer: “a Startlingly Good Report from Oracle (ORCL)”
Sep 14, 2024
We recently compiled a list titled Jim Cramer’s Latest Watchlist: 10 Stock Picks You Need to Know. In this article, we will look at where Oracle Corporation (NASDAQ:ORCL) stands among other stock picks in Jim Cramer's latest watchlist.
In a recent episode of Mad Money, Jim Cramer advised investors to hold onto their stocks, anticipating a rebound after the market’s downturn. This advice proved useful as the Dow rose by 484 points or 1.16% and the NASDAQ also climbed by 1.16%, indicating that selling during the market decline was not the best choice.
“Last week, I advised you to hold off on selling everything and just wait, as I believed that once the pain ended, we would see a rebound. The average investor saw gains, with the Dow up 484 points, or 1.16%, and the NASDAQ also climbing 1.16%. While it might not be a full recovery, it shows that selling into Friday’s downturn wasn’t the best strategy.”
Jim Cramer noted that the previous week was tough for economically sensitive and tech stocks, despite a mixed August employment report. This report suggested a balanced economic outlook, not too strong or weak, which initially seemed favorable for those hoping for Federal Reserve rate cuts. Despite this, Wall Street reacted negatively, shifting away from cyclical stocks to more recession-proof sectors like consumer goods and pharmaceuticals, with industries such as industrials and semiconductors being particularly affected.
Cramer observed that recession-proof stocks, such as pharmaceuticals and medical devices, have performed well recently but have seen significant gains, raising concerns about a potential correction.
“Today, recession-proof stocks like pharmaceuticals, drug wholesalers, and medical devices continued to perform well, which is dangerous as these stocks have seen parabolic gains and could be due for a correction.”
He highlighted that historically, when the Federal Reserve is about to cut rates, it signals a shift in investment strategy. With the Fed expected to ease rates soon, Cramer suggests investors consider moving away from recession-proof stocks and look into more cyclical companies that could benefit from economic stimulus. While investing in cyclical stocks during a downturn is challenging, the anticipated rate cuts could make these stocks more attractive. Cramer advises maintaining diversification but being ready to adjust investment strategies based on the economic outlook.
“Historically, when the Fed is about to start cutting rates, we know that it’s time to shift focus. With the Fed leaning towards easing and an expected rate cut next week, it’s time to consider moving away from recession-proof stocks and investing in more cyclical companies. While it’s challenging to buy cyclical stocks during a slowdown, anticipating that the Fed will boost the economy can make them strong investment opportunities. It’s important to maintain diversification but be ready to adjust as needed.”
Story continues
Our Methodology
This article reviews a recent episode of Jim Cramer’s Mad Money, where he talked about several stocks. From there, we picked ten companies and discussed how hedge funds are investing in them. Finally, we rank these companies from those least owned to those most owned by hedge funds.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Oracle Corporation (NASDAQ:ORCL)
Number of Hedge Fund Investors: 93 Jim Cramer highlighted a recent positive report from Oracle Corporation (NASDAQ:ORCL), noting that much of the good news is tied to the expansion of AI data centers. Cramer believes that the sell-off in chip stocks has been overdone, as the reasons for favoring this sector earlier in the year still hold true. He emphasized that the surge in AI spending is genuine, with significant investments in building the necessary infrastructure, as demonstrated by Oracle Corporation (NASDAQ:ORCL)’s latest results.
“This very evening, we got a startlingly good report from Oracle. A lot of the good news came in concert with data centers for AI. Hey, not bad! In the end, I think the chip stocks have sold off way too hard. Every reason we had to like this group earlier this year remains intact. The AI spending boom is very real, and there’s a ton of money being spent to build out the infrastructure, as we heard from Oracle this evening.
More importantly, there’s more to chips than AI. For the past couple of quarters, we’ve been exiting a period of oversupply in the semiconductor market, and we’re now finally seeing some excellent sales growth. Yes, we’re past the point of equilibrium—we’re going up!”
In Q1 2024, Oracle Corporation (NASDAQ:ORCL)’s earnings rose to $2.93 billion, or $1.03 per share, surpassing expectations. Its adjusted earnings of $1.39 per share also beat forecasts of $1.32. Revenue grew by 6.9% to $13.31 billion, driven mainly by its cloud services. The cloud segment, boosted by the acquisition of Cerner Corporation (NASDAQ:CERN), saw a 20% increase year-over-year, reaching $5.3 billion. Oracle Corporation (NASDAQ:ORCL)’s Infrastructure as a Service (IaaS) experienced a remarkable 42% growth, highlighting its successful focus on high-demand cloud and AI services.
Additionally, Oracle Corporation (NASDAQ:ORCL) has secured over $12 billion in AI contracts, positioning itself strongly in the AI field. Oracle Corporation (NASDAQ:ORCL)’s future revenue prospects are supported by a substantial $98 billion in remaining performance obligations. With its leadership in cloud technology and expanding AI contracts, Oracle Corporation (NASDAQ:ORCL) is set for continued growth, making it an attractive investment.
Carillon Eagle Growth & Income Fund stated the following regarding Oracle Corporation (NYSE:ORCL) in its Q2 2024 investor letter:
“Oracle Corporation (NYSE:ORCL) stock rose to all-time highs after the company announced better than expected cloud infrastructure revenue. Oracle signed dozens of new customers, including two leaders in generative artificial intelligence. The backlog remains, and strong growth appears poised to accelerate.”
Overall ORCL ranks 3rd on our list. While we acknowledge the potential of ORCL, our conviction lies in the belief that under the radar AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than the ones on our list but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article was originally published on Insider Monkey.
View comments
- Oracle's $28B Gamble On Cerner's AI-Driven Health Records System Backfires
May 20, 2024 · https://www.benzinga.com
: In 2021, Oracle acquired Cerner, a major EHR provider, with the intention of integrating its vast medical data into Oracle’s AI models to create the EHR of the future, reported Business Insider on Monday. However, Cerner’s EHR system, which was responsible for managing the electronic health records of a quarter of all American hospitals, including those run by the Pentagon and the Department of Veterans Affairs (VA), was found to be severely flawed. The system’s rollout at the VA, which serves 9 million veterans, was described as a “slow-moving catastrophe.” One feature of the EHR system caused over 11,000 orders for medical care to disappear into an “unknown queue,” resulting in thousands of patients not receiving the treatment their doctors had ordered. These errors were contributing factors in three deaths. Despite Ellison’s vision for a futuristic, AI-driven healthcare system, the acquisition of Cerner has become a significant liability for Oracle. The company is now racing against time to fix the dysfunctional system it inherited from Cerner before more veterans are injured or killed. : Oracle’s acquisition of Cerner was intended to revolutionize healthcare by leveraging AI to improve patient outcomes and reduce costs. However, the flawed EHR system has led to a series of patient deaths, tarnishing Oracle’s ambitious plans. Despite the setbacks, Oracle’s AI ambitions have not been entirely derailed. The company is reportedly in talks with ‘s artificial intelligence startup, xAI, for a potential $10 billion deal to rent Oracle’s AI servers. This deal, if finalized, would make xAI one of Oracle’s largest customers. The healthcare industry is increasingly turning to AI to streamline administrative tasks, optimize treatment plans, and enable more precise diagnostics. The global AI in healthcare market is expected to reach $148.4 billion by 2029, presenting a significant opportunity for AI companies like Oracle to drive innovation and transformation in the sector. Image Via Shutterstock Engineered by , Edited by The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
- Salucro Announces Expansion of Integrated Patient Payment Workflow Solution for Cerner Millennium® Customers
Jan 16, 2024 · businesswire.com
PHOENIX--(BUSINESS WIRE)--Salucro Healthcare Solutions, a leading healthcare payment technology company, today announced the general availability of its patient payment workflow integration for Cerner Millennium® customers. The intentionally designed integration will allow healthcare provider customers using the Cerner Millennium platform to process patient payments from their existing collection workflows, helping to improve revenue cycle efficiencies and the patient financial experience. “Thi.
- SALUCRO ANNOUNCES EXPANSION OF INTEGRATED PATIENT PAYMENT WORKFLOW SOLUTION FOR CERNER MILLENNIUM® CUSTOMERS
Jan 16, 2024
PHOENIX--(BUSINESS WIRE)--SALUCRO HEALTHCARE SOLUTIONS, A LEADING HEALTHCARE PAYMENT TECHNOLOGY COMPANY, TODAY ANNOUNCED THE GENERAL AVAILABILITY OF ITS PATIENT PAYMENT WORKFLOW INTEGRATION FOR CERNER MILLENNIUM® CUSTOMERS. THE INTENTIONALLY DESIGNED INTEGRATION WILL ALLOW HEALTHCARE PROVIDER CUSTOMERS USING THE CERNER MILLENNIUM PLATFORM TO PROCESS PATIENT PAYMENTS FROM THEIR EXISTING COLLECTION WORKFLOWS, HELPING TO IMPROVE REVENUE CYCLE EFFICIENCIES AND THE PATIENT FINANCIAL EXPERIENCE. “THI.
- Veteran Brings Lawsuit Against U.S. Government and Cerner After Defective Veterans Affairs Electronic Health Record (EHR) System Irreparably Delays Cancer Diagnosis, According to Luvera Law Firm
Dec 5, 2023 · businesswire.com
SPOKANE, Wash.--(BUSINESS WIRE)--Since the beginning of its botched rollout in 2020, the Cerner electronic health record (EHR) system at Mann-Grandstaff VA Medical Center has caused administrative delays, gaps in communication and other glitches with tragic consequences, according to a lawsuit filed by Luvera Law Firm on behalf of Charlie Bourg, a 68-year-old Army veteran, against the U.S. Government and Cerner. The lawsuit, filed in U.S. District Court, Eastern District of Washington on Dec. 1.
- VETERAN BRINGS LAWSUIT AGAINST U.S. GOVERNMENT AND CERNER AFTER DEFECTIVE VETERANS AFFAIRS ELECTRONIC HEALTH RECORD (EHR) SYSTEM IRREPARABLY DELAYS CANCER DIAGNOSIS, ACCORDING TO LUVERA LAW FIRM
Dec 5, 2023
SPOKANE, WASH.--(BUSINESS WIRE)--SINCE THE BEGINNING OF ITS BOTCHED ROLLOUT IN 2020, THE CERNER ELECTRONIC HEALTH RECORD (EHR) SYSTEM AT MANN-GRANDSTAFF VA MEDICAL CENTER HAS CAUSED ADMINISTRATIVE DELAYS, GAPS IN COMMUNICATION AND OTHER GLITCHES WITH TRAGIC CONSEQUENCES, ACCORDING TO A LAWSUIT FILED BY LUVERA LAW FIRM ON BEHALF OF CHARLIE BOURG, A 68-YEAR-OLD ARMY VETERAN, AGAINST THE U.S. GOVERNMENT AND CERNER. THE LAWSUIT, FILED IN U.S. DISTRICT COURT, EASTERN DISTRICT OF WASHINGTON ON DEC. 1.
